Search Results for: formulation development amorphous dispersion formu
Articles
AustinPx Expands KinetiSol Technology Commercial Access through Thermo Fisher Scientific Collaboration July 7, 2026
GEORGETOWN, Texas -- AustinPx, a contract development and manufacturing organization (CDMO) specializing in bioavailability enhancement for orally delivered small molecule...Codis To Acquire Catalent's Nottingham, UK Facility to Create Europe's Leading End-to-End Spray Dry Capability July 6, 2026
HAVERHILL, England, Codis, a global contract development and manufacturing organization (CDMO) specializing in spray drying, amorphous solid dispersions (ASDs), and...SPECIAL FEATURE - Bioavailability & Solubility: Experimental Techniques Combined With Computational Decision-Making Rapidly ID the Most Viable Enhancement Pathway April 17, 2026
Contributor Cindy H. Dubin highlights other ways formulators are relying on automation, such as Artificial Intelligence and Machine Learning, and how these tools are being combined with experimental confirmation to identify the most promising development strategies.
ORAL SUSPENSIONS - A New Standard in Oral Suspensions: Leveraging Novel Excipients for FDA Approval December 12, 2025
Mary Schuster introduces a new approach to perfecting oral suspension formulations, which is centered on the strategic use of a “novel” synthetic functional excipient, magnesium aluminometasilicate (MAS).
Hovione Completes Initial $100M Investment Cycle to Expand US Operations at New Jersey Manufacturing Campus October 20, 2025
Hovione, a fully-integrated global CDMO, today announced the completion of an initial multi-million-dollar investment cycle to expand its manufacturing campus...SPECIAL FEATURE - Excipients: Innovation in a Shifting Pharma Landscape October 7, 2025
Cindy H. Dubin speaks with several companies and highlights this innovation and reveals how excipient suppliers are doing their part to ensure a reliable, resilient, and compliance-driven supply chain.
EXCIPIENT TECHNOLOGY - Driving Oral Drug Delivery Innovation With Safe, Reliable Lipid Excipients October 7, 2025
Nick DiFranco, MEM, says amidst the uncertainty of novel ingredients and formulation techniques, lipid excipients provide a safe, proven platform for enhancing in vivo formulation performance, enabling innovation without sacrificing scalability or regulatory confidence.
Aenova expands its advanced technology portfolio with cutting-edge hot melt extrusion platform July 9, 2025
Starnberg, Germany, Aenova, a leading global contract development and manufacturing organization (CDMO), relies on various innovative technologies to improve the...SPECIAL FEATURE - Bioavailability & Solubility: The Promise of Novel Ingredients April 4, 2025
Contributor Cindy H. Dubin, speaks with several innovating companies to discuss the use of novel excipients as well as other methods and technologies for tackling bioavailability and solubility once and for all.
Catalent Boston Adds to Oral Spray Drying Capacity & Capabilities to Support Late-Stage Clinical Trials & Commercialization October 28, 2024
Catalent, the leading provider of oral drug development solutions, bioavailability enhancing technologies, and flexible manufacturing, has completed a series of...Hovione & Zerion Pharma Create Joint Venture to Further Expand Use of Dispersome Technology October 3, 2024
Hovione Farmaciência, S.A. and Zerion Pharma A/S recently announced they have expanded their partnership to accelerate the development of the...EXECUTIVE INTERVIEW - Lonza: Navigating Today’s Challenges in Drug Solubility & Bioavailability June 3, 2024
Adi Kaushal, Director and Technology Head, Bioavailability Enhancement at Lonza, discusses solubility and bioavailability challenges and Lonza’s approach.
Data From First Human Study Demonstrate Excellent Performance of Zerion Pharma’s Dispersome Technology May 13, 2024
Zerion Pharma A/S recently announced positive results from the first human clinical study of a Dispersome formulation of the drug...Elizabeth Hickman to Succeed Tim Scott as AustinPx CEO March 5, 2024
AustinPx, developers of the next generation amorphous dispersion platform, KinetiSol Technology, and a contract development and manufacturing organization (CDMO), recently announced Elizabeth Hickman, Chief Business Officer, will succeed….
SPECIAL FEATURE - Improving Bioavailability & Solubility: The Never-Ending Quest February 29, 2024
Contributor Cindy H. Dubin speaks with several companies to review their innovative technologies in this annual report on bioavailability and solubility.
PBPK MODELING - Critical Parameters for Simulating Oral Absorption Using PBPK Models February 29, 2024
Deanna Mudie, PhD, says with an increasing number of drugs posing absorption challenges, the ability to predict how a new molecule will behave in vivo is important, and being able to predict and mitigate absorption problems before they arise should help the project progress with fewer delays.
AustinPx Partners With Microsize on KinetiSol Technology, Partnership Strengthens Commercialization Options for AustinPx’s Clients January 31, 2024
AustinPx and Microsize recently announced the strategic partnership to accelerate the commercial application of AustinPx’s KinetiSol Technology platform. The collaboration will enable….
Nanoform Commenced Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide January 8, 2024
Nanoform Finland Plc recently announced it had completed the First Subject First Visit (FSFV) in a trial to evaluate the...Ascendia Named to 2023 Inc. 5000 List of America’s Fastest-Growing Private Companies for the Fourth Consecutive Year August 25, 2023
Ascendia Pharmaceuticals®, a leading specialty pharmaceutical contract development and manufacturing organization (CDMO) in North America, proudly announces it has been...EXECUTIVE INTERVIEW - Ascendia Pharmaceuticals: Innovative Solutions to Challenging Problems May 1, 2023
Jim Huang, PhD, CEO and Founder of Ascendia Pharmaceuticals, discusses how his company expanded its people, capabilities, and facilities to meet and exceed customer expectations from early to late-state development and how this investment allows Ascendia to continue be an expert in sophisticated formulations, as well as cGMP sterile and non-sterile clinical trial and commercial manufacturing.
Presentation: Strategies for Amorphous Solid Dispersion Product Development
In this presentation, Dr. Schlesinger demonstrates how to leverage a combination of measured and calculated molecular properties, bio-performance modeling, and a strategic understanding of the product TPP to identify a technology to enable exposure and an appropriate drug product design…..
